U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H28O5S
Molecular Weight 380.498
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ECABET

SMILES

[H][C@@]12CCC3=C(C=C(C(=C3)C(C)C)S(O)(=O)=O)[C@@]1(C)CCC[C@@]2(C)C(O)=O

InChI

InChIKey=IWCWQNVIUXZOMJ-MISYRCLQSA-N
InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H28O5S
Molecular Weight 380.498
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7574519 | https://www.ncbi.nlm.nih.gov/pubmed/7550119

Ecabet is an anti-ulcer agent, marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. Ecabet eradicates Helicobacter pylori infection in gastric ulcer patients. Antibacterial effect of ecabet is demonstrated at low pH, is mediated by inhibition of bacterial urease and accompanied by interference with TLR4 signaling and pepsin inhibition. Ecabet is also investigated for the treatment of dry eye syndrome.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P18314
Gene ID: NA
Gene Symbol: ureC
Target Organism: Enterobacter aerogenes (Aerobacter aerogenes)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Ecabet Na

Approved Use

Peptic ulcer disease
PubMed

PubMed

TitleDatePubMed
Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions.
1995 Jun
Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium.
1995 Jun
H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium.
2008 Feb 14
Patents

Sample Use Guides

For treatment of peptic ulcers, ecabet sodium is indicated orally, 1 g b.i.d. For treatment of dry eye syndrome, topical administration was used (one drop in study eye 4 times daily for 90 days).
Route of Administration: Other
In Vitro Use Guide
To measure bactericidal activity at pH 3.0, a liquid cultivation method was used. H. pylori NCTC 11637 was inoculated in 5 ml of brain heart infusion broth supplemented with 10% heat-inactivated fetal bovine serum and incubated at 378C for 48 h in an atmosphere of 5% O2–10% CO2–85% N2 with gyration. After rinsing with saline, bacterial cells were resuspended in saline to give about 109 CFU/ml. Reaction mixtures were prepared by adding 0.25 ml of an ecabet or BHA solution of citrate buffer supplemented with 10mM urea and incubated in a water bath at 37°C. Samples for viability (0.1 ml) were taken at 0, 15, 30, and 60 min. Viability was measured by the plate colony count technique. Ecabet showed concentration-dependent bactericidal effects at pHs 4.0 and 5.0, with MIC below 1 mg/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:05:17 GMT 2023
Edited
by admin
on Fri Dec 15 16:05:17 GMT 2023
Record UNII
2K02669KWP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ECABET
INN   MI   WHO-DD  
INN  
Official Name English
ECABET [MI]
Common Name English
ecabet [INN]
Common Name English
13-ISOPROPYL-12-SULFOPODOCARPA-8,11,13-TRIEN-15-OIC ACID
Common Name English
Ecabet [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
NCI_THESAURUS C29701
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
Code System Code Type Description
DRUG CENTRAL
981
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
SMS_ID
100000080484
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
EVMPD
SUB06441MIG
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
FDA UNII
2K02669KWP
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
NCI_THESAURUS
C65504
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
MESH
C061681
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
MERCK INDEX
m4805
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY Merck Index
CAS
33159-27-2
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
DRUG BANK
DB05265
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
INN
6742
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104585
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
PUBCHEM
65781
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID7046881
Created by admin on Fri Dec 15 16:05:17 GMT 2023 , Edited by admin on Fri Dec 15 16:05:17 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY